6-hydroxyhexaneamidine | 284029-67-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 6-hydroxyhexaneamidine
• 英文别名: 6-Hydroxyhexanimidamide
• CAS: 284029-67-0
• 化学式: C₆H₁₄N₂O
• mdl: MFCD19215080
• 分子量: 130.19
• InChiKey: HGGHHWSGCOAHGM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  9
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  70.1
• 氢给体数：
  3
• 氢受体数：
  2

文献信息

• [EN] OXADIAZOLE COMPOUNDS, THEIR PREPARATION AND USE<br/>[FR] COMPOSÉS OXADIAZOLE, LEUR PRÉPARATION ET LEUR UTILISATION
  申请人：PIRAMAL LIFE SCIENCES LTD

  公开号：WO2011104680A1

  公开（公告）日：2011-09-01

  The present invention relates to oxadiazole compounds in all their stereoisomeric and tautomeric forms and mixtures thereof in all ratios; and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable prodrugs and pharmaceutically acceptable polymorphs. The invention also relates to processes for the manufacture of the oxadiazole compounds and to pharmaceutical compositions containing them. The said compounds and their pharmaceutical compositions are useful in the treatment of cancer, particularly chronic myeloid leukemia (CML). The present invention further provides a method of treatment of cancer by administering a therapeutically effective amount of said compounds or their pharmaceutical compositions, to a mammal in need thereof.

  本发明涉及氧代唑化合物的所有立体异构体和互变异构体形式以及它们在所有比例的混合物中；以及它们的药学上可接受的盐、药学上可接受的溶剂化合物、药学上可接受的前药和药学上可接受的多形态。该发明还涉及制备氧代唑化合物的方法以及含有它们的药物组合物。所述化合物及其药物组合物可用于治疗癌症，特别是慢性髓样白血病（CML）。本发明还提供了一种治疗癌症的方法，即通过向需要的哺乳动物投予所述化合物或其药物组合物的治疗有效剂量。
• POLY(ADP-RIBOSE) POLYMERASE INHIBITORS CONSISTING OF PYRIMIDINE DERIVATIVES
  申请人：Meiji Seika Kaisha, Ltd.

  公开号：EP1142881A1

  公开（公告）日：2001-10-10

  A medicament for therapeutic and/or preventive treatment of a brain disease, which comprises a compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient: wherein R represents hydrogen atom, a C1-C8 alkyl group, a substituted C1-C8 alkyl group, an aryl group, a substituted aryl group, an aryl(C1-C8)alkyl group and the like; Y represents hydrogen atom or -C(R2)R3 (R2 and R3 represent hydrogen atom, a C1-C8 alkyl group, a C1-C8 alkoxy(C1-C8)alkyl group, a hydroxy(C1-C8)alkyl group and the like); symbol "a" represents single bond when Y represents hydrogen atom, or "a" represents double bound when Y represents -C(R2)R3; -A-B- represents -CH2-CH2-, -S-CH2-, -O-CH2-, -CH2-S-, -CH2-O-, -SO-CH2-, -CH2-SO-, -SO2-CH2-, or -CH2-SO2-; and Z represents -CH2- or single bond.

  一种用于治疗和/或预防脑部疾病的药物，其活性成分包括下式通式(I)所代表的化合物或其药学上可接受的盐： 其中 R 代表氢原子、C1-C8 烷基、取代的 C1-C8 烷基、芳基、取代的芳基、芳基（C1-C8）烷基等；Y 代表氢原子或 -C(R2)R3 （R2 和 R3 代表氢原子、C1-C8 烷基、C1-C8 烷氧基（C1-C8）烷基、羟基（C1-C8）烷基等）；符号 "a "在 Y 代表氢原子时代表单键，或 "a "在 Y 代表-C(R2)R3 时代表双键；-A-B-代表-CH2- -、-S- -、-O- -、- -S-、- -O-、-SO- -、- -SO-、-SO2-或- -SO2-；Z 代表- -或单键。
• Carbostyril derivatives
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP0382185B1

  公开（公告）日：1994-06-15
• OXYTOCIN ANTAGONIST
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP0602209A1

  公开（公告）日：1994-06-22
• OXADIAZOLE COMPOUNDS, THEIR PREPARATION AND USE
  申请人：Piramal Enterprises Limited

  公开号：EP2539327A1

  公开（公告）日：2013-01-02